Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript Summary
Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript Summary
The WATCHMAN franchise continues to show solid growth, and they have seen significant growth from their new AGENT drug-coated balloon.The following is a summary of the Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript:
以下是波士頓科學公司（BSX）業務更新業績會交流內容摘要：
Financial Performance:
金融業績：
Boston Scientific reported a robust year-to-date growth in its Cardiology division, with the U.S. market growing at 27% and the international market at 18%.
Their drug-eluting therapies, including stents and balloons, are seeing close to double-digit growth.
The WATCHMAN franchise continues to show solid growth, and they have seen significant growth from their new AGENT drug-coated balloon.
波士頓科學報告其心臟病學部門年初至今的強勁增長，美國市場增長27%，國際市場增長18%。
他們的藥物洗脫療法，包括支架和球囊，增長接近兩位數。
WATCHMAN系列產品持續展現穩健增長，同時他們的新一代AGENt藥塗球囊也取得了顯著增長。
Business Progress:
業務進展：
The company successfully launched their FARAVIEW mapping software and FARAWAVE NAV catheter, enhancing cardiology procedural efficiency.
They launched the Prime platform, building on the ACURATE platform, with enhanced features improving clinical outcomes.
Continued investment in complex PCI and mechanical circulatory support devices, aiming to start a U.S. IDE study by the end of 2025.
公司成功推出了FARAVIEW映射軟件和FARAWAVE NAV導管，提升心臟病學程序效率。
他們推出了Prime平台，基於ACURATE平台，擁有增強功能，改善臨床結果。
持續投資於複雜PCI和機械循環支持設備，旨在2025年底前開始一項美國IDE研究。
Opportunities:
機會：
The Cardiology market is projected to grow at a CAGR of 8% through 2027, indicating sustained market expansion opportunities.
Increased adoption of the FARAVIEW software and use in combination with the FARAWAVE NAV catheter provides opportunities for growth in procedural efficiency and effectiveness.
預計到2027年，心臟病學市場將以8％的複合年增長率增長，表明市場膨脹機會持續存在。
FARAVIEW軟件的增加採用並與FARAWAVE NAV導管結合使用，爲程序效率和效果的增長提供機會。
Risks:
風險：
Challenges in valve expansion in some cases, which may affect the effectiveness of implanted valves and could impact the reputation and sales if not managed properly.
在某些情況下，瓣膜擴張存在挑戰，可能影響植入瓣膜的效果，如果不得當處理，則可能影響聲譽和銷售。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
